Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

Leukemia

Volumn 29, Issue 5, 2015, Pages 1195-1201

  Khan, R ^a   Apewokin, S ^a   Grazziutti, M ^a   Yaccoby, S ^a   Epstein, J ^a   Van Rhee, F ^a   Rosenthal, A ^b   Waheed, S ^a   Usmani, S ^a,c   Atrash, S ^a   Kumar, S ^a   Hoering, A ^b   Crowley, J ^b   Shaughnessy, J D ^d   Barlogie, B ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b USA   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d Signal Genetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; C REACTIVE PROTEIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; HEMOGLOBIN; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; BORONIC ACID DERIVATIVE; CREATININE; PYRAZINE DERIVATIVE;

ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GENE EXPRESSION; GENE PROBE; GLOMERULUS FILTRATION; HUMAN; HYPOALBUMINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMACYTOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; BLOOD; BONE MARROW CELL; COMPLICATION; CYTOLOGY; DISEASE COURSE; DISEASE FREE SURVIVAL; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; METAPHASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PLASMA CELL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

AGED; BONE MARROW CELLS; BORONIC ACIDS; BORTEZOMIB; C-REACTIVE PROTEIN; CREATININE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; METAPHASE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRAZINES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84929266084     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.15     Document Type: Article

References (29)

1. Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 2013; 8: 2007-2017.
2. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693-1695.
3. Kyle RA, Rajkumar SV. Crietria for diagnosis, staging and risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
4. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22: 1485-1493.
5. Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007; 2: 440-444.
6. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.
7. Huston A, Brown J, Roodman GD. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Exp Hematol 2006; 34: 1616.
8. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181.
9. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
10. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
11. Perosa F, Minoia C, Favoino E, Prete M, Dammacco F. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Blood Cells Mol Dis 2009; 42: 71-76.
12. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-829.
13. Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 2014; 99: 148-154.
14. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385-390, 20.
15. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27-33.
16. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48: 337-341.
17. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893.
18. Jesus F, Miguel S, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med 2008; 359: 906-917.
19. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226-232.
20. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
21. Van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116: 1220-1227.
22. Nair B, van Rhee F, Shaughnessy Jr JD, Anaissie E, Szymonifka J, Hoering A et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115: 4168-4173.
23. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan G, Crowley J. Curing myeloma at last-defining criteria and providing the evidence. Blood 2014; 124: 3043-3051.
24. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
25. Kooman JP. Estimation of renal function in patients with chronic kidney disease. J Magn Reson Imaging 2009; 30: 1341-1346.
26. Mantel N. Evaluation or survival data and two new rank order statistics srising in ots evaluation. Cancer Chemo Rep 1966; 50: 163-170.
27. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
28. Cox DR. Regression models and life-tables (with discussion). J Royal Statist Soc Series B 1972; 34: 187-220.
29. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445.